Nanometric ion pair complexes of tobramycin forming microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

Sardo, Carla; Domenico, Enea Gino Di; Porsio, Barbara; Rocco, Davide De; Santucci, Roberto; Ascenzioni, Fiorentina; Giammona, Gaetano; Cavallaro, Gennara

doi:10.1016/j.ijpharm.2019.03.060

Cited by 4 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 184 ] Through the electrostatic interactions, two kinds of polyanions, α,β‐poly(N‐2‐hydroxyethyl)‐graft‐{ N ‐2‐ethylene[2‐poly(methacrylic acid sodium salt)}‐D,L‐aspartamide (PHEA‐IB‐pMANa + ) and its PEGylated analog PHEA‐PEG 2000 ‐IB‐pMANa + were complexed with tobramycin to generate nanometric ion‐paired complexes, which were able to improve the penetration through mucus barriers and reduce the side effects of tobramycin. [ 185 ] In another study, gentamicin has co‐assembled with p ( N ‐isopropylacrylamide‐b‐acrylic acid) triblock polymer (PNA) into a core‐shell nanoantibiotic through the Lewis acid‐base interactions. The multi‐responsiveness including pH, temperature, and ionic strength of PNA can be used to tailor the drug releasing profile of gentamicin from the system.…”

Section: Aminoglycoside‐based Biomaterialsmentioning

confidence: 99%

Aminoglycoside‐Based Biomaterials: From Material Design to Antibacterial and Gene Delivery Applications

Yang

Cheng

et al. 2021

Adv Funct Materials

View full text Add to dashboard Cite

Aminoglycosides are a family of naturally isolated or chemically semi‐synthesized antibiotics consisting of aminocyclitols with several amino and saccharide units. The unique molecule structures render aminoglycosides promising building blocks with high reactivity to perform various non‐covalent and covalent reactions, and they are further employed to rationally fabricate versatile materials, such as hydrogels, amphiphiles, hyperbranched polymers, biointerfaces, and nanoparticles. Despite aminoglycosides are widely used in clinics to treat bacterial infections, almost all the efforts are focused on molecular modifications to reduce their toxicities and overcome antibiotic resistance, while their actions as building blocks to construct biomaterials are scarcely discussed. In this feature article, the current progress on the rational design, emergent properties, and promising biological applications of aminoglycoside‐based biomaterials are summarized. It is believed that this paper may provide guidance to develop new biomaterials using natural functional molecules as building blocks, and start a new life of aminoglycosides from the view of materials science.

show abstract

Section: Aminoglycoside‐based Biomaterialsmentioning

confidence: 99%

Aminoglycoside‐Based Biomaterials: From Material Design to Antibacterial and Gene Delivery Applications

Yang

Cheng

et al. 2021

Adv Funct Materials

View full text Add to dashboard Cite

show abstract

“…Delivering this NiM formulation across cystic fibrosis (CF) mucus resulted in a nearly 5-fold increase in the concentration of ivacaftor in cells compared to free drug and a 2.5-fold increase compared to the unencapsulated nanoparticles. Mannitol-based NiM platforms have also incorporated mucolytics and stabilizers to deliver tobramycin for disrupting bacterial biofilms. , The efficacy of doubly penetrating nanoparticle designs for the treatment of CF has also been demonstrated with DNA–protein electrostatic assemblies for gene delivery . Coating these assemblies with PEG enabled mucopenetration, which was optimized at 40% coating density.…”

Section: Mucosae and Nanoparticle Designmentioning

confidence: 99%

“…Mannitol-based NiM platforms have also incorporated mucolytics and stabilizers to deliver tobramycin for disrupting bacterial biofilms. 122,123 The efficacy of doubly penetrating nanoparticle designs for the treatment of CF has also been demonstrated with DNA−protein electrostatic assemblies for gene delivery. 115 Coating these assemblies with PEG enabled mucopenetration, which was optimized at 40% coating density.…”

Section: Mucosae and Nanoparticle Designmentioning

confidence: 99%

Untangling Mucosal Drug Delivery: Engineering, Designing, and Testing Nanoparticles to Overcome the Mucus Barrier

Watchorn

Clasky

Prakash

et al. 2022

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Mucus is a complex viscoelastic gel and acts as a barrier covering much of the soft tissue in the human body. High vascularization and accessibility have motivated drug delivery to various mucosal surfaces; however, these benefits are hindered by the mucus layer. To overcome the mucus barrier, many nanomedicines have been developed, with the goal of improving the efficacy and bioavailability of drug payloads. Two major nanoparticle-based strategies have emerged to facilitate mucosal drug delivery, namely, mucoadhesion and mucopenetration. Generally, mucoadhesive nanoparticles promote interactions with mucus for immobilization and sustained drug release, whereas mucopenetrating nanoparticles diffuse through the mucus and enhance drug uptake. The choice of strategy depends on many factors pertaining to the structural and compositional characteristics of the target mucus and mucosa. While there have been promising results in preclinical studies, mucus−nanoparticle interactions remain poorly understood, thus limiting effective clinical translation. This article reviews nanomedicines designed with mucoadhesive or mucopenetrating properties for mucosal delivery, explores the influence of site-dependent physiological variation among mucosal surfaces on efficacy, transport, and bioavailability, and discusses the techniques and models used to investigate mucus−nanoparticle interactions. The effects of non-homeostatic perturbations on protein corona formation, mucus composition, and nanoparticle performance are discussed in the context of mucosal delivery. The complexity of the mucosal barrier necessitates consideration of the interplay between nanoparticle design, tissue-specific differences in mucus structure and composition, and homeostatic or disease-related changes to the mucus barrier to develop effective nanomedicines for mucosal delivery.

show abstract

Mucoadhesive Drug Delivery System in Chronic Respiratory Diseases

Garg

Garg²,

Pandey³

et al. 2022

Advanced Drug Delivery Strategies for Targeting Chronic Inflammatory Lung Diseases

View full text Add to dashboard Cite

Nanometric ion pair complexes of tobramycin forming microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

Cited by 4 publications

References 42 publications

Aminoglycoside‐Based Biomaterials: From Material Design to Antibacterial and Gene Delivery Applications

Aminoglycoside‐Based Biomaterials: From Material Design to Antibacterial and Gene Delivery Applications

Untangling Mucosal Drug Delivery: Engineering, Designing, and Testing Nanoparticles to Overcome the Mucus Barrier

Mucoadhesive Drug Delivery System in Chronic Respiratory Diseases

Contact Info

Product

Resources

About